Ajanta Pharma share news, announcements and annual reports
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Ajanta Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,508.80up ₹49.10 (1.42%)BSE ₹3,512.40
Share price at the NSE close on 30 Oct 2026. Previous close ₹3,459.70.
30 Oct: open ₹3,479.00, high ₹3,619.90, low ₹3,460.50
52-week range of traded prices to 30 Oct 2026
₹2,430.00Low, 30 Oct 2025₹3,796.00High, 18 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43,846 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.72
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.02
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.71%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 30.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.02
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,52,55826.6% delivered
Ajanta Pharma share news and announcements
812 announcements, routine notices left out, newest first. Page 12 of 17.
May 2014
Apr 2014
Mar 2014
Jan 2014
27 Jan · Results
17 Jan · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the third quarter ended December 31, 2013.14 Jan · Management
EXIM Bank has vide letter dated January 10, 2014 withdrawn nomination of Ms. Madhu Verma as Director of the Company. Accordingly, Ms. Madhu Verma ceases to be Director of the Company with immediate effect.9 Jan · Change in Company Secretary/Compliance Officer
Mr. Gaurang Shah has joined the organization w.e.f. January 6th, 2014. He has been appointed as Compliance Officer w.e.f. January 8th, 2014 in place of Mr. Deodatta Pandit.
Oct 2013
28 Oct · Results
18 Oct · Board meeting
To consider and approve, inter alia, the Unaudited Financial Results for the second quarter and half year ended September 30, 2013.
Sep 2013
19 Sep · Business
Executive Committee of the Board of Directors at its meeting held on September 19, 2013 has allotted 1,17,16,900 fully paid up equity shares of Rs. 5/- each. These shares have been allotted as a part of bonus issue. The ratio of bonus was 1:2 i.e. One (1) new fully paid up share of Rs. 5/- each for every Two (2) shares held. The said shares will rank pari-passu with the existing shares of the Company in all respects. In view of above the paid up capital of the company shall be increased to Rs. 17,57,53,500 consisting of 3,51,50,700 equity shares of Rs. 5/- each.5 Sep · Corporate action
Company has fixed Record Date as September 18, 2013 for the purpose of declaration and approval of issue of Bonus Equity Shares in the ratio of One (1) new fully paid-up Equity Shares of Rs.5/- each for every Two (2) fully paid-up shares held.
Aug 2013
Jul 2013
29 Jul · Corporate action
Board of Directors of the Company at its meeting held on July 29, 2013 have recommended issue of bonus shares to existing shareholders in the ratio of 1:2 subject to the receipt of approval of the equity shareholders by way of Postal Ballot.18 Jul · Board meeting
(1) To consider and approve, inter alia, the Unaudited Financial Results for the first quarter ended June 30, 2013. (2) To consider Bonus issue of shares.
Jun 2013
6 Jun · Dividend
Ajanta Pharma Limited had informed the Exchange that the date of payment of dividend on equity shares would be on after July 26, 2013, subject to approval of the shareholders at the forthcoming Annual General meeting. The Company has now informed the Exchange that subject to approval of the shareholders at the forthcoming Annual General Meeting, the date of payment of dividend on equity shares would be on or after July 29, 2013.
May 2013
22 May · Meeting
Company shall close its Equity Share Transfer Books for a period from July 22, 2013 to July 26, 2013 (both days inclusive) for the purpose of dividend. The dividend will be paid to the shareholders if the same is approved by the shareholders in the Annual General Meeting to be held on July 26, 2013.22 May · Meeting
Ajanta Pharma Limited had informed the Exchange that the Board of Directors of the Company at its meeting held on April 30, 2013 had recommended dividend @ Rs. 6.25 per equity share of the face value of Rs. 5/- each, subject to approval of shareholders at the ensuing Annual General Meeting to be held on July 13, 2013. The Company has now informed that the Company has inadvertently informed that the Annual General Meeting of the Company would be held on July 13, 2013. Further, the Company has informed that the Annual General Meeting of the Company will be held on July 26, 2013.21 May · Dividend
Date of payment of dividend on equity shares would be on after July 26, 2013, subject to approval of the shareholders at the forthcoming Annual General meeting.21 May · Management
Mr. Rajesh M. Agrawal and Mr. K H Viswanathan have been appointed as Additional Directors w.e.f. April 30, 2013.Further, Mr. Rajesh M. Agrawal is appointed as Joint Managing Director effective from May 01, 2013 subject to the approval of shareholders at the ensuing Annual General Meeting.
Apr 2013
30 Apr · Results
30 Apr · Business
Compensation Committee of Directors at its meeting held on April 30, 2013, has allotted 16,800 fully paid up equity shares of Rs.5/- each. These shares have been allotted upon exercising of options granted to the employees under Employees Stock Option Scheme - 2011 of the Company. In view of the above, the issued and paid up capital of the Company shall be increased to Rs.11,71,69,000 consisting 2,34,33,800 equity shares of Rs.5/- each.30 Apr · Dividend
That the Board of Directors of the Company at its meeting held on April 30, 2013 have recommended dividend @ Rs. 6.25 per equity share of the face value of Rs. 5/- each, subject to approval of shareholders at the ensuing Annual General Meeting to be held on July 13, 2013.